These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32366491)

  • 21. Validation of two predictive models for survival in pulmonary arterial hypertension.
    Sitbon O; Benza RL; Badesch DB; Barst RJ; Elliott CG; Gressin V; Lemarié JC; Miller DP; Muros-Le Rouzic E; Simonneau G; Frost AE; Farber HW; Humbert M; McGoon MD
    Eur Respir J; 2015 Jul; 46(1):152-64. PubMed ID: 25837032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk stratification in pulmonary arterial hypertension.
    Weatherald J; Boucly A; Sitbon O
    Curr Opin Pulm Med; 2018 Sep; 24(5):407-415. PubMed ID: 30004992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological Treatment of Pulmonary Arterial Hypertension in Australia: Current Trends and Challenges.
    Anderson J; Lavender M; Lau E; Celermajer D; Collins N; Dwyer N; Feenstra J; Horrigan M; Keating D; Keogh A; Kotlyar E; Ng B; Proudman S; Steele P; Thakkar V; Weintraub R; Whitford H; Williams T; Wrobel J; Strange G
    Heart Lung Circ; 2020 Oct; 29(10):1459-1468. PubMed ID: 32280014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk assessment in patients with functional class II pulmonary arterial hypertension: Comparison of physician gestalt with ESC/ERS and the REVEAL 2.0 risk score.
    Sahay S; Tonelli AR; Selej M; Watson Z; Benza RL
    PLoS One; 2020; 15(11):e0241504. PubMed ID: 33175857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contemporary risk scores predict clinical worsening in pulmonary arterial hypertension - An analysis of FREEDOM-EV.
    Benza RL; Gomberg-Maitland M; Farber HW; Vizza CD; Broderick M; Holdstock L; Nelsen AC; Deng C; Rao Y; White RJ
    J Heart Lung Transplant; 2022 Nov; 41(11):1572-1580. PubMed ID: 36117055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) pulmonary hypertension prediction model in a unique population and utility in the prediction of long-term survival.
    Cogswell R; Kobashigawa E; McGlothlin D; Shaw R; De Marco T
    J Heart Lung Transplant; 2012 Nov; 31(11):1165-70. PubMed ID: 23062726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients.
    Delcroix M; Staehler G; Gall H; Grünig E; Held M; Halank M; Klose H; Vonk-Noordegraaf A; Rosenkranz S; Pepke-Zaba J; Opitz CF; Gibbs JSR; Lange TJ; Tsangaris I; Huscher D; Pittrow D; Olsson KM; Hoeper MM
    Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30337446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of the REVEAL pulmonary arterial hypertension prediction model using non-invasive and routinely measured parameters.
    Cogswell R; Pritzker M; De Marco T
    J Heart Lung Transplant; 2014 Apr; 33(4):382-7. PubMed ID: 24534251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension.
    Benza RL; Gomberg-Maitland M; Miller DP; Frost A; Frantz RP; Foreman AJ; Badesch DB; McGoon MD
    Chest; 2012 Feb; 141(2):354-362. PubMed ID: 21680644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can a Bayesian Belief Network Be Used to Estimate 1-year Survival in Patients With Bone Sarcomas?
    Nandra R; Parry M; Forsberg J; Grimer R
    Clin Orthop Relat Res; 2017 Jun; 475(6):1681-1689. PubMed ID: 28397168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are Guideline-recommended Risk Classification Schemes in Pulmonary Hypertension Adequately Robust to Guide the Real-world Setting?
    Akaslan D; Aslanger E; Ataş H; Kocakaya D; Yıldızeli B; Mutlu B
    Balkan Med J; 2023 May; 40(3):188-196. PubMed ID: 37000114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension.
    Benza RL; Kanwar MK; Raina A; Scott JV; Zhao CL; Selej M; Elliott CG; Farber HW
    Chest; 2021 Jan; 159(1):337-346. PubMed ID: 32882243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation effect of COMPERA 2.0 risk assessment model on prognosis of Chinese patients with pulmonary arterial hypertension].
    Liang YR; Yang YC; Yang BL; Zeng QX; Liu BY; Zhao Q; Luo Q; Zhao ZH; Yang T; Liu ZH; Xiong CM
    Zhonghua Yi Xue Za Zhi; 2023 May; 103(18):1410-1416. PubMed ID: 37150694
    [No Abstract]   [Full Text] [Related]  

  • 34. [Risk stratification methods and their significance in pulmonary arterial hypertension].
    Avdeev SN; Tsareva NA
    Ter Arkh; 2019 Sep; 91(9):150-157. PubMed ID: 32598827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Guideline implementation and early risk assessment in pulmonary arterial hypertension associated with congenital heart disease: A retrospective cohort study.
    Deng X; Jin B; Li S; Li Y; Zhou H; Wu Y; Yan M; Hu Y; Qiu Q; Zhang G; Zheng X
    Clin Respir J; 2019 Nov; 13(11):693-699. PubMed ID: 31419027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of race on survival in pulmonary arterial hypertension: Results from the REVEAL registry.
    Medrek S; Sahay S; Zhao C; Selej M; Frost A
    J Heart Lung Transplant; 2020 Apr; 39(4):321-330. PubMed ID: 32067864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Congenital heart disease with pulmonary artery hypertension in an Asian cohort-initial report from TACHYON (TAiwan congenital heart disease associated with pulmonarY arterial hypertension) registry.
    Chiu SN; Weng KP; Lin MC; Wang JN; Hwang BT; Dai ZK; Lin SM; Chang JS; Lin IC; Wu MH; Lu CW; Lin MT; Chen CA; Hua YC; Wu JM; Wang JK;
    Int J Cardiol; 2020 Oct; 317():49-55. PubMed ID: 32522677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can We Estimate Short- and Intermediate-term Survival in Patients Undergoing Surgery for Metastatic Bone Disease?
    Forsberg JA; Wedin R; Boland PJ; Healey JH
    Clin Orthop Relat Res; 2017 Apr; 475(4):1252-1261. PubMed ID: 27909972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).
    Benza RL; Miller DP; Gomberg-Maitland M; Frantz RP; Foreman AJ; Coffey CS; Frost A; Barst RJ; Badesch DB; Elliott CG; Liou TG; McGoon MD
    Circulation; 2010 Jul; 122(2):164-72. PubMed ID: 20585012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can A Multivariate Model for Survival Estimation in Skeletal Metastases (PATHFx) Be Externally Validated Using Japanese Patients?
    Ogura K; Gokita T; Shinoda Y; Kawano H; Takagi T; Ae K; Kawai A; Wedin R; Forsberg JA
    Clin Orthop Relat Res; 2017 Sep; 475(9):2263-2270. PubMed ID: 28560532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.